Compare CVS Health Corp (CVS) vs Invesco DB Commodity Index Tracking Fund (DBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Invesco DB Commodity Index Tracking Fund — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while Invesco DB Commodity Index Tracking Fund trades at $32.8 (market cap $1.93B). The key difference: CVS Health Corp is far larger — about 58.3× Invesco DB Commodity Index Tracking Fund's market cap, and CVS Health Corp pays a 3.02% dividend while Invesco DB Commodity Index Tracking Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Invesco DB Commodity Index Tracking Fund for 61 Days on average.
| CVS | DBC | |
|---|---|---|
Market Cap | $112.49B | $1.93B |
Volume | 8,467,392 | 569,977 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $110.60 | $33.68 |
52-Week Low | $70.08 | $22.07 |
Typical Hold Time | 83 Days | 61 Days |
Enterprise Value | $174.83B | — |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
DBC trades at $32.51, down 0.55% on the day, with a bullish technical signal from moving averages. The company reported $82.59M in revenue and $22.38M net income for 2024, showing improved profitability from 2023's loss. Cash flow from operations was strong at $431.54M, contributing to a healthy balance sheet with $1.28B in shareholder equity and minimal debt.
The outlook appears favorable with positive earnings momentum and robust operational cash flow. Key risks include revenue volatility, as seen in historical fluctuations, and dependence on commodity market conditions. Analyst sentiment is constructive given the bullish technical indicators and improved financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →
